Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib + Capecitabine in PIK3CA-mutant Metastatic Colorectal Cancer After Two Prior Chemotherapies
KCT0005726Phase 2Completed
- Sponsor
- Ministry of Health & Welfare
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib, capecitabine in metastatic colon cancer (mCRC), sponsored by Ministry of Health & Welfare. Started Feb 2021; status: completed.
02
Drugs
alpelisibcapecitabine
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on KCT0005726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005726.